about
2,3,7,8 Tetrachlorodibenzo-p-dioxin induction of cytochrome P4501A in cultured rat and human hepatocytesScreening for human ADME/Tox drug properties in drug discovery.Human hepatocytes: isolation, cryopreservation and applications in drug development.A review of the common properties of drugs with idiosyncratic hepatotoxicity and the "multiple determinant hypothesis" for the manifestation of idiosyncratic drug toxicity.High content analysis of an in vitro model for metabolic toxicity: results with the model toxicants 4-aminophenol and cyclophosphamide.A comprehensive approach for drug safety assessment.Evaluation of INK4A promoter methylation using pyrosequencing and circulating cell-free DNA from patients with hepatocellular carcinoma.Effects of cytochrome P450 inducers on 17alpha-ethinyloestradiol (EE2) conjugation by primary human hepatocytesPrimary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies.An evaluation of the roles of mammalian cell mutation assays in the testing of chemical genotoxicity.Biomarkers and human hepatocytes.In vitro human hepatocyte-based experimental systems for the evaluation of human drug metabolism, drug-drug interactions, and drug toxicity in drug development.Definition of metabolism-dependent xenobiotic toxicity with co-cultures of human hepatocytes and mouse 3T3 fibroblasts in the novel integrated discrete multiple organ co-culture (IdMOC) experimental system: results with model toxicants aflatoxin B1,Cytotoxicity of eight cigarette smoke condensates in three test systems: comparisons between assays and condensates.Preclinical evaluation of drug-drug interaction potential: present status of the application of primary human hepatocytes in the evaluation of cytochrome P450 induction.Substrates of human hepatic cytochrome P450 3A4.Polybrominated biphenyl induction of cytochrome P450 mixed function oxidase activity in primary rat and human hepatocytes.Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes.Cytotoxicity of ethylene oxide/propylene oxide copolymers in cultured mammalian cells.Spontaneous frequency of 6-thioguanine resistant mutants in CHO-AS52 cells after prolonged culturing in the absence of selective agents.Mutagenicity of mono-, di- and tri-nitropyrenes in Chinese hamster ovary cells.Studies on the etiology of acute acalculous cholecystitis: the effect of lipopolysaccharide on human gallbladder mucosal cells.Applications of primary human hepatocytes in the evaluation of pharmacokinetic drug-drug interactions: evaluation of model drugs terfenadine and rifampin.Simplification of the CHO/HGPRT mutation assay through the growth of Chinese hamster ovary cells as unattached cultures.A comparison of aroclor 1254-induced and uninduced rat liver microsomes to human liver microsomes in phenytoin O-deethylation, coumarin 7-hydroxylation, tolbutamide 4-hydroxylation, S-mephenytoin 4'-hydroxylation, chloroxazone 6-hydroxylation and teSpecies comparison in P450 induction: effects of dexamethasone, omeprazole, and rifampin on P450 isoforms 1A and 3A in primary cultured hepatocytes from man, Sprague-Dawley rat, minipig, and beagle dog.Differential in vitro hepatotoxicity of troglitazone and rosiglitazone among cryopreserved human hepatocytes from 37 donors.Correlation between troglitazone cytotoxicity and drug metabolic enzyme activities in cryopreserved human hepatocytes.Identification of glutathione conjugates of troglitazone in human hepatocytes.Reactivity of atropaldehyde, a felbamate metabolite in human liver tissue in vitro.Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A.Open letter to the European Commission: scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science, and risk assessment principles.An in vitro lung epithelial cell system for evaluating the potential toxicity of inhalable materials.Maintenance of liver functions in rat hepatocytes cultured as spheroids in a rotating wall vessel.Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin.Applications of microarrays with toxicologically relevant genes (tox genes) for the evaluation of chemical toxicants in Sprague Dawley rats in vivo and human hepatocytes in vitro.Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes.An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles.Evaluation of luciferin-isopropyl acetal as a CYP3A4 substrate for human hepatocytes: effects of organic solvents, cytochrome P450 (P450) inhibitors, and P450 inducers.
P50
Q28373922-27E9F7E8-BE42-419B-8BA4-771E836C13CBQ34194499-3C82C550-E563-448F-9B25-300D64522634Q34608510-EA65B944-50BE-44D4-8042-9347D9F0D7EFQ34979818-5F200620-CF49-4F3B-B66A-20DF1DAC6964Q35265775-EDC17D66-C785-4B87-9D90-E02597EC57F4Q35937235-6908031A-2950-4FE6-A5A2-D4172E1646A7Q35940554-2AE62D90-3D0A-47AB-976C-4359CD234CDEQ36053808-0652C45C-DEE5-4294-9481-A3C9BD54392CQ36761687-3DDD4AA4-48B5-47D2-8E81-E8A4A52CAFD7Q37497102-09F7172B-1C43-4C91-ABE8-D08DF3DDD5FFQ38187449-2002F7D4-8FEC-48A6-8AE6-9DD6C577FBF7Q38209985-61F3CDF3-84D4-4EFD-AB68-7F7B46B9EE5EQ39341079-12EAC658-E6D6-4ED9-8946-7A70F41B6B0CQ39666122-FD49E358-C753-4FF0-AE5B-6C95298F5300Q40875533-D2D44F20-33DB-47B7-8246-21919C053D9CQ40944769-2A7CCA0E-BE12-4AC5-B3C6-7A2C1FB409A9Q40985311-F78EE55A-A92E-44A9-A911-E0E6CC2D79B1Q41076169-36576C73-1060-4EA9-9CE7-8C89FA6BE395Q41375212-FCF6A33A-B198-4698-B2E7-E67678525029Q41749292-FA422D33-46CE-4EA2-AA7F-F72DDEEBE7CCQ42254833-99B97B55-9409-4D9F-85B9-F5C875D8EBA0Q42495805-A8E0BDE9-25D1-4308-B03C-13D05B46E24EQ42547670-002371F5-C97D-4790-A91B-70F02B7C961BQ43594587-6F7DD426-F1CF-4757-83E1-2D0DE6CD3C42Q43597478-789F81FA-CF21-4E7E-A1A7-7D787E741012Q43597482-6D3F9C9E-04B5-4641-9DE7-76CEB67325CDQ44193642-01343A0A-2D71-4D50-A882-618C32360D2EQ44193646-AD70071D-7A24-444A-B346-1F1A1562B71EQ44193648-C2A32E47-1E2B-4F5E-B0F5-A38A46EAD7F6Q44193652-8D018659-6452-4C40-89AA-FD5AD64614DDQ44285527-34A8DCAF-07CC-4937-A51C-F4F8FCF7DD3CQ44414390-35544345-ADF7-4147-A62E-4E5B72D6957BQ44517251-BA632ABB-4C00-49A8-B979-E32AF4AB4B80Q44533420-DDAD3926-3D9F-48FF-A0DF-1AD45536416AQ44646549-0F9AF807-5324-4AFC-A4B6-8A0D781BEA44Q44879058-E3A58236-1A21-400A-91B6-595F863382C6Q44928051-0F770230-1FE3-430D-A8A1-A8C1853E1558Q45145643-97DDF6B6-0EE9-44FD-AAEF-1E08FEB7A8F4Q45408563-BC787303-BE9D-40EE-9A02-25125F80B2D8Q46006815-21A8892A-316F-4DC2-880E-B1128CD31B46
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Albert Li
@ast
Albert Li
@en
Albert Li
@es
Albert Li
@nl
type
label
Albert Li
@ast
Albert Li
@en
Albert Li
@es
Albert Li
@nl
prefLabel
Albert Li
@ast
Albert Li
@en
Albert Li
@es
Albert Li
@nl
P106
P1153
8652691500
P21
P31
P496
0000-0001-5772-6265